ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /化合物

3-フェノキシ-α-メチルベンゼン酢酸

Fenoprofen

HCID 3342
ノートを作成反応を作成見積依頼を出す
印刷プレビュー

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
29679-58-1
標準SMILES
CC(C(=O)O)c1cccc(Oc2ccccc2)c1
InChIKey
RDJGLLICXDHJDY-UHFFFAOYSA-N
分子式
C15H14O3
平均分子量
242.27 g/mol
単同位体質量
242.09429431

概要

Fenoprofen is a monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic, a cyclooxygenase 2 inhibitor, a cyclooxygenase 1 inhibitor and a drug allergen. It is a conjugate acid of a fenoprofen(1-).

名称と識別子

優先名称
Fenoprofen
IUPAC
2-(3-phenoxyphenyl)propanoic acid
現地名
3-フェノキシ-α-メチルベンゼン酢酸
英語名
2-(3-phenoxyphenyl)propionic acid
分子式
C15H14O3
分子量
242.27

名称と別名

fenoprofen2-(3-Phenoxyphenyl)propanoic acid31879-05-7FenoprofeneFenoprofenoFenoprofenumNalfonalpha-Methyl-3-phenoxybenzeneacetic acid(+-)-m-Phenoxyhydratropic acid2-(m-phenoxyphenyl)propionic acid3-Phenoxyhydratropic acidLilly-53858
名称をさらに表示
α-メチル-3-フェノキシベンゼン酢酸3-フェノキシ-α-メチルベンゼン酢酸2-(3-フェノキシフェニル)プロピオン酸2-(3-フェノキシフェニル)プロパン酸Fenoprofen D3Einecs 249-770-12-(3-Phenoxyphenyl)Fenoprofen, racemic mixtureα-Methyl-3-phenoxybenzeneacetic acidBenzeneacetic acid, a-methyl-3-phenoxy-Benzeneacetic acid, α-methyl-3-phenoxy-Benzeneacetic acid, α-methyl-3-phenoxy-
(+-)-2-(3-Phenoxyphenyl)propionic acidalpha-(m-phenoxyphenyl)propionic acidRA33EAC7KYNSC-757813CHEBI:5004DL-2-(3-phenoxyphenyl)propionic acidBenzeneacetic acid, alpha-methyl-3-phenoxy-, (+-)-DTXSID9023045

物性

構造計算による物性補完中

XLogP
3.3
極性表面積
46.5 Ų
水素結合供与体数
1
水素結合受容体数
3
回転可能結合数
4
重原子数
18
形式電荷
0
複雑度
271

実験および物理化学的性質

LogP · 2 件

3.1

3.45

Color/FormVISCOUS OIL
Solubility · 2 件

Slight (calcium salt)

8.11e-02 g/L

Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

Pharmaceuticals

Boiling Point168-171 °C @ 0.11 MM HG
Melting Point168-171
Refractive IndexINDEX OF REFRACTION: 1.5742 @ 25 °C/D
Physical DescriptionSolid
Dissociation Constants · 2 件

4.5

PKA= 7.3

Collision Cross Section157.19 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Interactions · 4 件

WHEN FENOPROFEN WAS ADDED TO REGIMEN OF...PT WITH RHEUMATOID ARTHRITIS WHO WERE RECEIVING CORTICOSTEROID OR GOLD THERAPY, THERE WAS SOME EVIDENCE THAT DOSE OF STEROID COULD BE REDUCED & COMBINATION WITH GOLD WAS MORE EFFECTIVE.

FOOD DELAYS ABSORPTION...& REDUCES PEAK PLASMA CONCN (ABOUT 30%) & TOTAL ABSORPTION (ABOUT 20%), AS DOES COADMIN OF...ANTACIDS.

/PLASMA PROTEIN/ BINDING OF FENOPROFEN IS INHIBITED BY CONCOMITANT ADMIN OF INDOMETHACIN & PHENYLBUTAZONE... PLASMA T/2 OF FENOPROFEN IS DECR BY ASPIRIN...

FENPROFEN & PROPOXYPHENE ARE ADDITIVE WHEN GIVEN TOGETHER.

Hepatotoxicity · 1 件

Prospective studies show that up to 15% of patients taking fenoprofen experience at least transient serum aminotransferase elevations. These elevations are generally transient, mild and asymptomatic, and may resolve even with drug continuation. Marked aminotransferase elevations (above 3 times the upper limit of normal (ULN) occur in less than 1% of patients.

Human Toxicity Excerpts · 5 件

MOST COMMON ADVERSE REACTIONS /ORAL ADMIN/...GI EFFECTS (EG, DYSPEPSIA, CONSTIPATION, NAUSEA, VOMITING)...FEW CASES OF ULCERATION... CNS REACTIONS INCL DROWSINESS, DIZZINESS, HEADACHE, NERVOUSNESS, & CONFUSION. PRURITUS, RASH, SWEATING, PALPITATIONS, TREMOR, TINNITUS, BLURRED VISION, & DECR HEARING...SENSITIVITY TO DRUG...

ELEVATIONS OF SERUM TRANSAMINASE, LACTIC DEHYDROGENASE, & ALKALINE PHOSPHATASE LEVELS...IN SOME PT. DECR IN HEMOGLOBIN & HEMATOCRIT...OCCASIONALLY. FENOPROFEN REDUCES PLATELET AGGREGATION & ADHESIVENESS & INCR BLEEDING TIME /ORAL ADMIN/.

.../FENOPROFEN, ORALLY/ EFFECTIVENESS IN RHEUMATOID ARTHRITIS APPEARS... COMPARABLE TO...ASPIRIN &...INCIDENCE OF GI REACTIONS & AMT OF GI BLEEDING IS LESS THAN WITH ASPIRIN.

...DRUGS /INCL FENOPROFEN/ HAVE BEEN ASSOC WITH FATAL GI HEMORRHAGE IN RARE CASES.

For more Human Toxicity Excerpts (Complete) data for FENOPROFEN (10 total), please visit the HSDB record page.

Drug Induced Liver Injury · 6 件

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

fenoprofen

Nalfon®

NSAIDs

化学と産業

薬理情報

ATC Code · 2 件

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding99% to albumin.
Pharmacodynamics · 1 件

Fenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect.

Mechanism of Action · 2 件

Fenoprofen's exact mode of action is unknown, but it is thought that prostaglandin synthetase inhibition is involved. Fenoprofen has been shown to inhibit prostaglandin synthetase isolated from bovine seminal vesicles.

LIKE ASPIRIN, FENOPROFEN INHIBITS PROSTAGLANDIN SYNTHETASE, BUT SIGNIFICANCE OF THIS ACTION IN RELATION TO CLINICAL EFFECTS PRODUCED IS NOT KNOWN.

Biological Half-Life · 3 件

Plasma half-life is approximately 3 hours.

関連反応

34 件
反応記録を作成
HRID 317727 の反応式
HRID 317727生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (8/10)
HRID 358284 の反応式
HRID 358284生成物としてuspto-grants-1984_08
HRID 358285 の反応式
HRID 358285生成物としてuspto-grants-1984_08
HRID 442230 の反応式
HRID 442230反応物としてuspto-grants-1977_08
HRID 461426 の反応式
HRID 461426反応物としてuspto-grants-1977_12
HRID 614262 の反応式
HRID 614262生成物としてuspto-grants-1979_03
HRID 614657 の反応式
HRID 614657反応物としてuspto-grants-1979_03
HRID 662292 の反応式
HRID 662292生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (3/10)
1 / 5 ページ

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
その他の操作
ノートを作成反応を作成見積依頼を出す

データベース識別子

CAS
29679-58-1、31879-05-7、34597-40-5
PubChem CID
3342
DTXSID
DTXSID9023045
ChEMBL
CHEMBL1297
ChEBI
CHEBI:5004
UNII
RA33EAC7KY
EC Number
249-770-1、250-850-3
Nikkaji
J286.928D
沸点
168 · 168-171 °C(Press: 0.11 Torr)
比重(密度)
1.183 · 1.183±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · Store at -20°C
溶解性
100 mg/mL · DMSO : 100 mg/mL (412.76 mM; Need ultrasonic)
酸解離定数(Pka)
4.2 · 4.20±0.10(Predicted)
外見
Oil to Thick Oil
色
Colourless
EPAの化学物質情報
-3 · Benzeneacetic acid, ?-methyl-3-phenoxy- (29679-58-1)

8

most-DILI-concern

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

hs_code
2918999090

...RAPIDLY ABSORBED AFTER ORAL ADMIN; PEAK PLASMA LEVEL OCCURS WITHIN 90 MIN. IT HAS PLASMA T/2 OF ABOUT 160 MIN, WHICH DOES NOT APPEAR...DOSE DEPENDENT. ABSORPTION & AVAILABILITY ARE REDUCED WHEN...AGENT IS GIVEN WITH FOOD, BUT ARE NOT AFFECTED BY CONCOMITANT ADMIN OF AN ANTACID...

...T/2...2.5-3 HR...

Metabolism/Metabolites · 3 件

About 90% of a single oral dose is eliminated within 24 hours as fenoprofen glucuronide and 4'-hydroxyfenoprofen glucuronide, the major urinary metabolites of fenoprofen.

...FENOPROFEN...FOUND TO YIELD 2 URINARY GLUCURONIDES IN MAN. ONE...ACCOUNTING FOR ALMOST 1/2 THE DOSE, IS THE ACYL GLUCURONIDE... THE SECOND...ACCOUNTING FOR THE OTHER 1/2 OF THE DOSE, IS A GLUCURONIDE OF THE PHENOLIC DERIVATIVE /OF FENOPROFEN/...AN ACYL GLUCURONIDE WITH A FREE PHENOLIC GROUP.

...FENOPROFEN...FOUND TO YIELD SMALL AMT OF ACID-LABILE CONJUGATE BEING NEITHER A GLYCINE NOR A GLUTAMINE CONJUGATE...

FDA Pharmacological Classification · 6 件

RA33EAC7KY

FENOPROFEN

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Fenoprofen is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of fenoprofen is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2 件

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 6 件

Rapidly absorbed under fasting conditions, and peak plasma levels of 50 µg/mL are achieved within 2 hours after oral administration of 600 mg doses.

...RAPIDLY ABSORBED AFTER ORAL ADMIN; PEAK PLASMA LEVEL OCCURS WITHIN 90 MIN. ...ABSORPTION & AVAILABILITY ARE REDUCED WHEN...AGENT IS GIVEN WITH FOOD, BUT ARE NOT AFFECTED BY CONCOMITANT ADMIN OF AN ANTACID...

...FENOPROFEN...IS WELL ABSORBED FROM GI TRACT AS NA OR CA SALT, & IS RAPIDLY CLEARED BY KIDNEYS...

IN USUAL DOSES, FENOPROFEN...WELL ABSORBED (OVER 80%), RAPIDLY /ACHIEVES/... STEADY-STATE BLOOD LEVELS...HIGHLY PROTEIN BOUND (95-99%). ...BIOTRANSFORMED IN LIVER, & METABOLITES ARE EXCRETED IN URINE. ...T/2...2.5-3 HR...

FOLLOWING ABSORPTION, FENOPROFEN IS METAB & EXCRETED ALMOST EXCLUSIVELY IN URINE IN CONJUGATED FORM. ...IS HIGHLY BOUND TO PLASMA PROTEIN, & IT MAY DISPLACE OTHER PROTEIN-BOUND DRUGS FROM THEIR BINDING SITES, LEADING TO DRUG INTERACTIONS.

HUMAN PLASMA & URINE PHARMACOKINETICS AFTER ORAL & IV ADMIN OF FENOPROFEN.

Cellular LocationsCytoplasm
Metabolite PathwaysFenoprofen Action Pathway

用途と製造

UsesMEDICATION
Methods of ManufacturingMARSHALL, FRENCH PATENT 2,015,718 CORRESPONDING TO US PATENT 3,600,437 (1970, 1971 TO LILLY).
Formulations/Preparations · 2 件

LILLY 69323; FENOPRON; FEPRONA /CALCIUM SALT DIHYDRATE/

NALFON (DISTA). ORAL: CAPSULES 300 MG

Use ClassificationPharmaceuticals

応用分野

使用Fenoprofen is a positive allosteric modulators at melanocortin receptor 3 for treatment of inflammatory diseases in human and mouse model.